

Stewart A Factor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2609848/publications.pdf>

Version: 2024-02-01

184
papers

13,979
citations

23500

58
h-index

22764

112
g-index

207
all docs

207
docs citations

207
times ranked

10263
citing authors

#	ARTICLE	IF	CITATIONS
1	Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. <i>Movement Disorders</i> , 2017, 32, 739-749.	2.2	649
2	Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group. <i>Movement Disorders</i> , 2007, 22, 1061-1068.	2.2	474
3	Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an) Tj ETQq1 1 0.784314 rgBT /Overlock 469	1.5	469
4	Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease. <i>Archives of Neurology</i> , 2004, 61, 1044-53.	4.9	446
5	Safety and efficacy of NeuroBloc (botulinum toxin type B) in type Aâ€“resistant cervical dystonia. <i>Neurology</i> , 1999, 53, 1431-1431.	1.5	427
6	Safety and efficacy of NeuroBloc (botulinum toxin type B) in type Aâ€“responsive cervical dystonia. <i>Neurology</i> , 1999, 53, 1439-1439.	1.5	371
7	Sleep disorders and sleep effect in Parkinson's disease. <i>Movement Disorders</i> , 1990, 5, 280-285.	2.2	350
8	KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. <i>American Journal of Psychiatry</i> , 2017, 174, 476-484.	4.0	339
9	The Parkinson's progression markers initiative (PPMI) â€“ establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	1.7	330
10	Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 40.	3.8	327
11	Randomized controlled trial of deutetrabenazine for tardive dyskinesia. <i>Neurology</i> , 2017, 88, 2003-2010.	1.5	296
12	Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Psychiatry</i> , 2017, 4, 595-604.	3.7	291
13	Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease. <i>Neurology</i> , 2007, 68, 1108-1115.	1.5	288
14	A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. <i>Neurology</i> , 2012, 78, 1229-1236.	1.5	284
15	Psychogenic movement disorders: frequency, clinical profile, and characteristics.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 59, 406-412.	0.9	272
16	Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. <i>Neurology</i> , 1997, 49, 701-707.	1.5	252
17	Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 201-211.	2.2	247
18	Longitudinal outcome of Parkinsonâ€™s disease patients with psychosis. <i>Neurology</i> , 2003, 60, 1756-1761.	1.5	242

#	ARTICLE	IF	CITATIONS
19	A Randomized, Double-blind, Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events. <i>Archives of Neurology</i> , 2001, 58, 1385.	4.9	232
20	Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015, 78, 248-257.	2.8	224
21	Clinical Presentation and Pharmacological Therapy in Corticobasal Degeneration. <i>Archives of Neurology</i> , 1998, 55, 957.	4.9	196
22	Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease. <i>Science Advances</i> , 2020, 6, .	4.7	186
23	Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa. <i>Neuropsychopharmacology</i> , 2012, 37, 213-246.	2.8	185
24	The focal dystonias: Current views and challenges for future research. <i>Movement Disorders</i> , 2013, 28, 926-943.	2.2	184
25	LRRK2 levels in immune cells are increased in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2017, 3, 11.	2.5	177
26	APOE, MAPT, and SNCA Genes and Cognitive Performance in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 1405.	4.5	172
27	The emergin role of clozapine in the treatment of movement disorders. <i>Movement Disorders</i> , 1997, 12, 483-496.	2.2	164
28	Physiology of freezing of gait. <i>Annals of Neurology</i> , 2016, 80, 644-659.	2.8	160
29	GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 95-102.	2.2	158
30	Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. <i>Npj Parkinson's Disease</i> , 2020, 6, 11.	2.5	140
31	Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 2078-2081.	2.2	138
32	Clinical comparison of tardive and idiopathic cervical dystonia. <i>Movement Disorders</i> , 1998, 13, 486-489.	2.2	135
33	Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease. <i>Movement Disorders</i> , 2018, 33, 793-804.	2.2	130
34	Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. <i>Annals of Neurology</i> , 2007, 62, 137-144.	2.8	129
35	Diagnosis and Treatment of Dystonia. <i>Neurologic Clinics</i> , 2015, 33, 77-100.	0.8	120
36	Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. <i>Magnetic Resonance Imaging</i> , 2014, 32, 1301-1306.	1.0	115

#	ARTICLE	IF	CITATIONS
37	Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson's disease: an observational and case-control study. <i>Npj Parkinson's Disease</i> , 2015, 1, .	2.5	108
38	Parkinson's disease: drug-induced psychiatric states. <i>Advances in Neurology</i> , 1995, 65, 115-38.	0.8	108
39	NBI-8854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. <i>Movement Disorders</i> , 2015, 30, 1681-1687.	2.2	105
40	Mild cognitive impairment in Parkinson's disease: Subtypes and motor characteristics. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 177-180.	1.1	99
41	Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 692-697.	1.1	99
42	Primary progressive freezing gait: A syndrome with many causes. <i>Neurology</i> , 2006, 66, 411-414.	1.5	97
43	Freezing of gait: understanding the complexity of an enigmatic phenomenon. <i>Brain</i> , 2020, 143, 14-30.	3.7	97
44	The Natural History of the Syndrome of Primary Progressive Freezing Gait. <i>Archives of Neurology</i> , 2002, 59, 1778.	4.9	93
45	Exploring gene-environment interactions in Parkinson's disease. <i>Human Genetics</i> , 2008, 123, 257-265.	1.8	92
46	Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder. <i>Neurotherapeutics</i> , 2014, 11, 166-176.	2.1	92
47	The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2015, 10, 50.	4.4	91
48	Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 564-568.	0.9	90
49	Clozapine prevents recurrence of psychosis in Parkinson's disease. <i>Movement Disorders</i> , 1992, 7, 125-131.	2.2	86
50	The clinical spectrum of freezing of gait in atypical parkinsonism. <i>Movement Disorders</i> , 2008, 23, S431-S438.	2.2	86
51	Parkinson's disease and LRRK2: Frequency of a common mutation in U.S. movement disorder clinics. <i>Movement Disorders</i> , 2006, 21, 519-523.	2.2	84
52	Trauma as an etiology of parkinsonism: A historical review of the concept. <i>Movement Disorders</i> , 1988, 3, 30-36.	2.2	82
53	Failure of recognition of drug-induced parkinsonism in the elderly. <i>Movement Disorders</i> , 2008, 23, 401-404.	2.2	81
54	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Neurology</i> , The, 2020, 19, 135-144.	4.9	80

#	ARTICLE	IF	CITATIONS
55	Quality improvement in neurology: Parkinson disease update quality measurement set. <i>Neurology</i> , 2016, 86, 2278-2283.	1.5	76
56	The Effects of Valbenazine in Participants with Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1344-1350.	1.1	67
57	Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited. <i>Human Brain Mapping</i> , 2016, 37, 2547-2556.	1.9	66
58	Lingual protrusion dystonia: Frequency, etiology and botulinum toxin therapy. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 438-441.	1.1	63
59	Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2190-2195.	2.2	61
60	Genetic association between α -synuclein and idiopathic parkinson's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 1222-1230.	1.1	60
61	Long-Term Comparative Experience with Tolcapone and Entacapone in Advanced Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2001, 24, 295-299.	0.2	59
62	Cognitive correlates of hallucinations and delusions in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2014, 347, 316-321.	0.3	55
63	Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1995, 7, 304-307.	0.9	54
64	Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. <i>Movement Disorders</i> , 2005, 20, 1152-1160.	2.2	54
65	Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. <i>Journal of Neurology</i> , 2016, 263, 1188-1194.	1.8	53
66	Recent developments in drug-induced movement disorders: a mixed picture. <i>Lancet Neurology</i> , The, 2019, 18, 880-890.	4.9	52
67	Freezing of gait subtypes have different cognitive correlates in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1359-1364.	1.1	51
68	Cognitive and Motor Function in Long-Duration <i>PARKIN</i> -Associated Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 62.	4.5	49
69	The role of neurotransmitters in the development of Parkinson's disease-related psychosis. <i>European Journal of Neurology</i> , 2017, 24, 1244-1254.	1.7	48
70	<i>In vivo</i> detection of lateral/ventral tier nigral degeneration in Parkinson's disease. <i>Human Brain Mapping</i> , 2017, 38, 2627-2634.	1.9	47
71	Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 4, 266.	1.1	47
72	Dystonia and Tremor. <i>Neurology</i> , 2021, 96, e563-e574.	1.5	46

#	ARTICLE	IF	CITATIONS
73	Identification of genetic modifiers of age-at-onset for familial Parkinson's disease. Human Molecular Genetics, 2016, 25, 3849-3862.	1.4	44
74	DOPAMINE AGONISTS. Medical Clinics of North America, 1999, 83, 415-443.	1.1	43
75	Tardive Dyskinesia. Current Treatment Options in Neurology, 2011, 13, 231-241.	0.7	43
76	Literature review. Neurology, 2004, 62, S12-7.	1.5	43
77	Cervical dystonia severity scale reliability study. Movement Disorders, 2001, 16, 1086-1090.	2.2	42
78	Focal dystonia secondary to cerebral toxoplasmosis in a patient with acquired immune deficiency syndrome. Movement Disorders, 1991, 6, 69-72.	2.2	40
79	Basal ganglia infarction as a possible cause of cervical dystonia. Movement Disorders, 1993, 8, 213-216.	2.2	40
80	Current Status of Symptomatic Medical Therapy in Parkinson's Disease. Neurotherapeutics, 2008, 5, 164-180.	2.1	40
81	Long-term safety and efficacy of pramipexole in subjects with fluctuating Parkinson's disease. Movement Disorders, 2013, 28, 817-820.	2.2	40
82	Freezing of Gait can persist after an acute levodopa challenge in Parkinson's disease. Npj Parkinson's Disease, 2019, 5, 25.	2.5	40
83	Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts. Movement Disorders, 2019, 34, 416-419.	2.2	40
84	Hemichorea-hemiballismus associated with acquired immune deficiency syndrome and cerebral toxoplasmosis. Movement Disorders, 1989, 4, 266-273.	2.2	39
85	Early combination therapy with bromocriptine and levodopa in parkinson's disease. Movement Disorders, 1993, 8, 257-262.	2.2	39
86	Fatal Parkinsonism's hyperpyrexia syndrome in a Parkinson's disease patient while actively treated with deep brain stimulation. Movement Disorders, 2007, 22, 148-148.	2.2	39
87	Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic. Tremor and Other Hyperkinetic Movements, 2014, 4, 266.	1.1	39
88	Delayed-onset dystonia associated with corticospinal tract dysfunction. Movement Disorders, 1988, 3, 201-210.	2.2	38
89	Focal myopathy as a cause of anterocollis in Parkinsonism. Movement Disorders, 2001, 16, 754-756.	2.2	38
90	Threatening Auditory Hallucinations and Cotard Syndrome in Parkinson Disease. Clinical Neuropharmacology, 2004, 27, 205-207.	0.2	38

#	ARTICLE	IF	CITATIONS
91	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS). <i>JAMA Neurology</i> , 2016, 73, 102.	4.5	38
92	Adult-onset dystonia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2011, 100, 481-511.	1.0	37
93	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 56, 211.e1-211.e7.	1.5	37
94	Possible tardive dystonia resulting from clozapine therapy. <i>Movement Disorders</i> , 1999, 14, 873-874.	2.2	36
95	Clinimetric testing of the comprehensive cervical dystonia rating scale. <i>Movement Disorders</i> , 2016, 31, 563-569.	2.2	36
96	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. <i>Movement Disorders</i> , 2018, 33, 1769-1776.	2.2	36
97	Valproic acid-induced parkinsonism: Levodopa responsiveness with dyskinesia. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 758-760.	1.1	35
98	Disentangling Stigma from Functional Neurological Disorders: Conference Report and Roadmap for the Future. <i>Frontiers in Neurology</i> , 2017, 8, 106.	1.1	35
99	Parkinson's disease: The treatment of drug-induced hallucinations and psychosis. <i>Current Neurology and Neuroscience Reports</i> , 2001, 1, 320-328.	2.0	32
100	VMAT2 inhibitors for the treatment of tardive dyskinesia. <i>Journal of the Neurological Sciences</i> , 2018, 389, 43-47.	0.3	32
101	Dystonia in AIDS: Report of four cases. <i>Movement Disorders</i> , 2003, 18, 1492-1498.	2.2	31
102	A Functional Magnetic Resonance Imaging Study of Head Movements in Cervical Dystonia. <i>Frontiers in Neurology</i> , 2016, 7, 201.	1.1	29
103	Adult-onset tics associated with peripheral injury. <i>Movement Disorders</i> , 1997, 12, 1052-1055.	2.2	27
104	Movement Disorders Emergencies Part 1. <i>Archives of Neurology</i> , 2011, 68, 567-72.	4.9	27
105	Temporal profile of improvement of tardive dystonia after globus pallidus deep brain stimulation. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 116-119.	1.1	27
106	Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2018-319918.	0.9	25
107	Saccades in Progressive Supranuclear Palsy "Maladapted, Irregular, Curved, and Slow. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 671-681.	0.8	24
108	Paroxysmal tremor and orofacial dyskinesia secondary to a bipterin synthesis defect. <i>Neurology</i> , 1991, 41, 930-930.	1.5	24

#	ARTICLE	IF	CITATIONS
109	Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. <i>CNS Spectrums</i> , 2022, 27, 208-217.	0.7	23
110	Propranolol therapy for Tardive dyskinesia: A retrospective examination. <i>Parkinsonism and Related Disorders</i> , 2016, 32, 124-126.	1.1	22
111	Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 644-646.	1.1	21
112	Abnormal center of mass feedback responses during balance: A potential biomarker of falls in Parkinson's disease. <i>PLoS ONE</i> , 2021, 16, e0252119.	1.1	21
113	Oromandibular Dystonia: A Clinical Examination of 2,020 Cases. <i>Frontiers in Neurology</i> , 2021, 12, 700714.	1.1	20
114	Psychodynamic Psychotherapy for Functional (Psychogenic) Movement Disorders. <i>Journal of Movement Disorders</i> , 2017, 10, 40-44.	0.7	19
115	Mosaic pattern of gliosis in the neostriatum of a north american man with craniocervical dystonia and parkinsonism. <i>Movement Disorders</i> , 1997, 12, 783-789.	2.2	18
116	Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia. <i>Movement Disorders</i> , 2002, 17, 158-161.	2.2	18
117	Globus pallidus deep brain stimulation for adult-onset axial dystonia. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1279-1282.	1.1	17
118	A case of lithium-induced parkinsonism presenting with typical motor symptoms of Parkinson's disease in a bipolar patient. <i>International Psychogeriatrics</i> , 2016, 28, 2101-2104.	0.6	17
119	Sleep Correlates of Trait Executive Function and Memory in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 49-54.	1.5	16
120	Imaging Parkinsonian Pathology in Substantia Nigra with MRI. <i>Current Radiology Reports</i> , 2018, 6, 1.	0.4	16
121	Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1210-1218.	0.9	16
122	Management of Tardive Syndrome: Medications and Surgical Treatments. <i>Neurotherapeutics</i> , 2020, 17, 1694-1712.	2.1	16
123	Discussion of Research Priorities for Gait Disorders in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 253-263.	2.2	16
124	Propranolol therapy for tardive dyskinesia revisited. <i>Movement Disorders</i> , 2012, 27, 1703-1703.	2.2	15
125	Non-human primate FOG develops with advanced parkinsonism induced by MPTP Treatment. <i>Experimental Neurology</i> , 2012, 237, 464-469.	2.0	15
126	Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients: A Randomized Phase 2 Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3682.	1.0	15

#	ARTICLE	IF	CITATIONS
127	Exploring human-genome gut-microbiome interaction in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 74.	2.5	15
128	Acetazolamide therapy of menstrual-related fluctuations in parkinson's disease. <i>Movement Disorders</i> , 1993, 8, 240-241.	2.2	14
129	Promise of Pharmacogenomics for Drug Discovery, Treatment and Prevention of Parkinson's Disease. A Perspective. <i>Neurotherapeutics</i> , 2014, 11, 111-116.	2.1	14
130	Potential mechanisms for low uric acid in Parkinson disease. <i>Journal of Neural Transmission</i> , 2016, 123, 365-370.	1.4	14
131	Chorea caused by lithium intoxication: A case report and literature review. <i>Movement Disorders</i> , 1996, 11, 733-737.	2.2	13
132	Multimodal assessment of nigrosomal degeneration in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 102-107.	1.1	13
133	Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysis. <i>Npj Parkinson's Disease</i> , 2021, 7, 105.	2.5	13
134	Persistent extrapyramidal syndrome with dystonia and rigidity caused by combined metoclopramide and prochlorperazine therapy. <i>Southern Medical Journal</i> , 1991, 84, 626-8.	0.3	13
135	A Neurodegenerative Disease Sleep Questionnaire: Principal component analysis in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2014, 336, 243-246.	0.3	12
136	Plasticity-related gene 3 (<i>LPPR1</i>) and age at diagnosis of Parkinson disease. <i>Neurology: Genetics</i> , 2018, 4, e271.	0.9	12
137	Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. <i>Neurology</i> , 2014, 83, 1388-1389.	1.5	11
138	Clinical outcomes of globus pallidus deep brain stimulation for Parkinson disease: a comparison of intraoperative MRI and MER-guided lead placement. <i>Journal of Neurosurgery</i> , 2021, 134, 1072-1082.	0.9	11
139	Parkinson's disease: Initial treatment with levodopa or dopamine agonists. <i>Current Treatment Options in Neurology</i> , 2001, 3, 479-493.	0.7	10
140	Parkinsonism-Hyperpyrexia Syndrome in Parkinson's Disease. , 2005, , 29-40.		10
141	Pilot Single-Blind Trial of AbobotulinumtoxinA in Oromandibular Dystonia. <i>Neurotherapeutics</i> , 2018, 15, 452-458.	2.1	10
142	Lurasidone-Induced Tardive Syndrome. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 601-604.	0.8	10
143	Diagnosing functional neurological disorder: seeing the whole picture. <i>CNS Spectrums</i> , 2021, 26, 593-600.	0.7	10
144	Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 264-267.	2.2	10

#	ARTICLE	IF	CITATIONS
145	Stepping up to meet the challenge of freezing of gait in Parkinson's disease. <i>Translational Neurodegeneration</i> , 2022, 11, 23.	3.6	10
146	Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1989, 52, 83-88.	0.9	9
147	Hold that pose: capturing cervical dystonia's head deviation severity from video. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 684-694.	1.7	9
148	Peripheral catecholamine output in Parkinson's disease: Effects of drug treatment. <i>Experimental Neurology</i> , 1995, 131, 64-68.	2.0	8
149	Parkinsonism-Hyperpyrexia Syndrome in Parkinson's Disease. , 2013, , 29-41.		8
150	Lower Limb Rigidity Is Associated with Frequent Falls in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 446-451.	0.8	8
151	Diphasic Worsening of Freezing of Gait in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 325-328.	0.8	8
152	A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease "OFF" episodes. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 169-177.	1.4	8
153	The effect of dancing on dystonia. <i>Movement Disorders</i> , 1996, 11, 225-227.	2.2	7
154	Of Monkeys and Men: Analysis of the Phase 2 Double-Blind, Sham-Surgery Controlled, Randomized Trial of AAV2-Neurturin Gene Therapy for Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 345-348.	2.0	7
155	Glutamate Receptor Gene GRIN2A, Coffee, and Parkinson Disease. <i>PLoS Genetics</i> , 2014, 10, e1004774.	1.5	7
156	Parkinson's disease: Motor fluctuations. <i>Current Treatment Options in Neurology</i> , 1999, 1, 21-32.	0.7	6
157	Perception of whole-body motion during balance perturbations is impaired in Parkinson's disease and is associated with balance impairment. <i>Gait and Posture</i> , 2020, 76, 44-50.	0.6	6
158	Seven-Year Experience From the National Institute of Neurological Disorders and Stroke's "Supported Network for Excellence in Neuroscience Clinical Trials. <i>JAMA Neurology</i> , 2020, 77, 755.	4.5	6
159	A metabolomic study of cervical dystonia. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 98-103.	1.1	6
160	It's tricky: Rating alleviating maneuvers in cervical dystonia. <i>Journal of the Neurological Sciences</i> , 2020, 419, 117205.	0.3	6
161	Head tremor in cervical dystonia: Quantifying severity with computer vision. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120154.	0.3	6
162	Vitamin E therapy in Parkinson's disease. <i>Advances in Neurology</i> , 1990, 53, 457-61.	0.8	6

#	ARTICLE	IF	CITATIONS
163	An 18F-FDG PET study of cervical muscle in parkinsonian anterocollis. Journal of the Neurological Sciences, 2014, 340, 174-177.	0.3	5
164	Freezing of gait: A rare delayed complication of whole brain radiation. Parkinsonism and Related Disorders, 2016, 29, 129-130.	1.1	5
165	A Multi-center Genome-wide Association Study of Cervical Dystonia. Movement Disorders, 2021, 36, 2795-2801.	2.2	5
166	Current and future treatments in multiple system atrophy. Current Treatment Options in Neurology, 2007, 9, 210-223.	0.7	3
167	Freezing of gait that disappears: Should there be rest before rehab?. Parkinsonism and Related Disorders, 2016, 28, 169-170.	1.1	3
168	A double-blind evaluation of ciladopa in Parkinson's disease. Movement Disorders, 1987, 2, 211-217.	2.2	2
169	The "shirt collar sign" of cervical dystonia. International Journal of Neuroscience, 2017, 127, 466-468.	0.8	2
170	Affective Correlates of Psychosis in Parkinson's Disease. Movement Disorders Clinical Practice, 2017, 4, 225-230.	0.8	2
171	Neuromechanical Assessment of Activated vs. Resting Leg Rigidity Using the Pendulum Test Is Associated With a Fall History in People With Parkinson's Disease. Frontiers in Human Neuroscience, 2020, 14, 602595.	1.0	2
172	Pseudonystagmus in progressive supranuclear palsy. Journal of the Neurological Sciences, 2022, 434, 120157.	0.3	2
173	Restless Legs Symptoms and Periodic Leg Movements in Sleep Among Patients with Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 1339-1344.	1.5	2
174	Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study. Frontiers in Neurology, 2022, 13, 773999.	1.1	1
175	Cramps and Spasms. , 2008, , 263-281.		0
176	Editorial: Neurotherapeutics of Movement Disorders. Neurotherapeutics, 2014, 11, 3-5.	2.1	0
177	The role of polymyography in the treatment of cervical dystonia: the authors reply. Journal of Neurology, 2016, 263, 1665-1665.	1.8	0
178	Camptocormia: a consensus for grading on a curve. Parkinsonism and Related Disorders, 2018, 52, 6.	1.1	0
179	Medical Therapy for Fluctuations in Parkinson's Disease. Current Clinical Neurology, 2019, , 11-15.	0.1	0
180	Treatment of Multiple System Atrophy. Current Clinical Neurology, 2019, , 141-145.	0.1	0

#	ARTICLE	IF	CITATIONS
181	139 Early Response with Valbenazine and Long-Term Symptom Reduction in Patients with Tardive Dyskinesia: Post Hoc Analysis of the KINECT 3 Study. CNS Spectrums, 2020, 25, 288-289.	0.7	0
182	Parkinsonism-Hyperpyrexia Syndrome in Parkinson's Disease. Current Clinical Neurology, 2022, , 77-93.	0.1	0
183	Nonmotor Symptoms in Dystonia. Medical Psychiatry, 2006, , 289-300.	0.2	0
184	Nonmotor symptoms in dystonia. , 2012, , 320-338.		0